- Date: April 03, 2017
Cemark, one of the projects chosen during the previous edition of the CaixaImpulse programme, has already begun the testing phase of its research.
Endometrial cancer is the fourth most common in women and it affects more than 280,000 people per year. The number of cases per year has gone up by 21% since 2008. This is the reason why the researchers at Vall d’Hebron Hospital have created a standard diagnosis based on the observation of malignant cells in an endometrial biopsy.
As Eva Colas—a member of the Biomedical Research Group in Gynaecology of the Vall d'Hebron Research Institute (VHIR)—explains, the problem is that sometimes, it is not possible to obtain enough cells for the test to be valid. This situation happens in 22% of cases and leads to additional invasive testing. This is why the team wants to make diagnosis possible without performing tedious and invasive rounds of testing.
The greatest problem lies in the diagnosis, as it is a very tedious process which many women have to go through. One of the symptoms that can warn patients and doctors is abnormal vaginal bleeding, although it is a very unspecific sign.
The CaixaImpulse programme has provided consultancy services and funding to the researchers of Cemark. And they have been able to diagnose this cancer using endometrial fluid by performing a simple test based on the presence of two proteins.
Cemark’s work does not end here, as it still has to go through clinical practice, the valuation process and final kit development. “We have to continue working with the same motivation and desire to innovate together with a great team, as we get closer to the finish line”, concludes Eva Colas.
November 17, 2017
On 10 November, participants pitched their valorisation plans to the CaixaImpulse Valorisation Panel, who will confirm the grants offered to each project. The upcoming months will be devoted to execute the actions included in their respective plans.
November 14, 2017
World Diabetes Day is the largest campaign of its kind to raise awareness of the metabolic disease. CaixaImpulse's APODRUG project aims to develop a new treatment for diabetic patients with an associated fatty liver disease.
November 10, 2017
GlyCardial Diagnostics, which was founded last September, has raised an investment of €2.4 million from Caixa Capital Risc, with participation from the Healthequity SCR fund.